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ABSTRACT
Background
Through major efforts to reduce costs and expand access to antiretroviral therapy worldwide,
widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable
even in severely resource-constrained settings. However, the potential epidemiologic impact of
treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined.
In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out.
Methods and Findings
We used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to
investigate a range of possible positive and negative health outcomes under alternative
scenarios that reflect varying implementation of prevention and treatment. In baseline
projections, reflecting ‘‘business as usual,’’ the numbers of new infections and AIDS deaths are
expected to continue rising. In two scenarios representing treatment-centered strategies, with
different assumptions about the impact of treatment on transmissibility and behavior, the
change in the total number of new infections through 2020 ranges from a 10% increase to a 6%
reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A
prevention-centered strategy provides greater reductions in incidence (36%) and mortality
reductions similar to those of the treatment-centered scenarios by 2020, but more modest
mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined
response, the expected benefits are substantial—29 million averted infections (55%) and 10
million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment
scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined
response are considerably smaller—9 million averted infections (17%) and 6 million averted
deaths (16%). Combining treatment with effective prevention efforts could reduce the resource
needs for treatment dramatically in the long term. In the various scenarios the numbers of
people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed
effects, to 4.2 million in a combined response scenario with positive treatment–prevention
synergies.
Conclusions
These analyses demonstrate the importance of integrating expanded care activities with
prevention activities if there are to be long-term reductions in the number of new HIV
infections and significant declines in AIDS mortality. Treatment can enable more effective
prevention, and prevention makes treatment affordable. Sustained progress in the global fight
against HIV/AIDS will be attained only through a comprehensive response.
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In June 2001, heads of state and government convened a
United Nations Special Session on HIV/AIDS and adopted
unanimously the ‘‘Declaration of Commitment on HIV/AIDS’’
[1]. In preparation for that session, Schwartla ¨nder et al.
published an estimate of the resource needs for an expanded
global response to the epidemic, which called for around
US$10 billion for the ﬁght against HIV/AIDS in 2005 [2]. In
2002, on the occasion of the 14th International AIDS
conference in Barcelona, Spain, Stover et al. showed that
such an immediate and expanded response in low- and
middle-income countries could reverse the course of the HIV/
AIDS epidemic and avert nearly 30 million infections through
2010 [3]. Today, more resources are available for the ﬁght
against HIV than ever before, but global efforts to confront
the epidemic continue to disappoint. Worldwide in 2004,
more people were living with HIV and more people died of
AIDS than in any previous year [4]. In sub-Saharan Africa,
home to two-thirds of all people living with HIV/AIDS, and
three out of four people dying from AIDS [4], only one in 50
persons with advanced disease had access to life-saving
medicines at the beginning of 2004 [5].
The theme of the 15th International AIDS Conference in
Bangkok last summer was timely and relevant. ‘‘Access for
All’’ calls for extending to all of those in need both sufﬁcient
resources and a set of proven interventions to prevent new
infections and save lives through effective treatment. Recent
developments in HIV treatment, with simple combination
therapies priced at less than US$150 per year—unthinkable
just a short time ago—were a major driver of discussions
during the conference. Widespread access to effective
antiretroviral therapy (ART) for people living with HIV/AIDS
is now conceivable even in countries with severely limited
resources.
The World Health Organization and its partners in the
Joint United Nations Programme on HIV/AIDS have deﬁned
an ambitious ‘‘3b y5 ’’ target of 3 million people on ART—
half of those in most urgent need—by the end of 2005. The
potential epidemiologic impact of large-scale roll-out of
treatment programs, however, remains uncertain. Experience
to date is limited, and comes mostly from Western countries
and Brazil. While declines in AIDS mortality in the
industrialized world have been impressive [6,7,8], many of
these success stories have been accompanied by a resurgence
in HIV incidence due to increasing risk behavior as emphasis
shifted from prevention to treatment in the 1990s [9,10,11].
Will the extension of ART to millions who suffer from AIDS
in developing countries be the long-awaited breakthrough in
the response to HIV, or will the emphasis on treatment
detract from prevention efforts, and thus hamper AIDS
control in the medium and long term? The experience in
high-income countries underscores the potential perils of
failing to adapt prevention strategies to an environment in
which life-saving treatment becomes available on a large
scale; however, more favorable outcomes in some settings
[12,13] indicate that rising risk behavior is not an inevitable
outcome of increased treatment access.
In our previous analysis of the potential beneﬁts of a
comprehensive package of preventive interventions [3], we
noted that these prevention effects would be achieved only in
the presence of wide-scale treatment and political support.
The two intervening years have seen a dramatic rise in both
momentum and ﬁnancial resources for ART scale-up, but the
potential epidemiologic impact of treatment in the context of
a broader strategy for HIV/AIDS control has not yet been
examined. In this paper, we quantify the opportunities and
potential risks of large-scale treatment roll-out. The results of
this analysis will be informative for all regions and countries,
independent of the level and stage of the epidemic. However,
since three of four deaths from AIDS occur in sub-Saharan
Africa, successes and failures in rolling out treatments
immediately will have the most dramatic effects in this
region. We therefore focus our analyses and discussions in
this paper on the HIV epidemics in sub-Saharan Africa.
Methods
Projections of HIV Epidemics in Sub-Saharan Africa
Baseline projections of HIV epidemics in sub-Saharan
Africa have been developed by the Joint United Nations
Programme on HIV/AIDS and the World Health Organiza-
tion based on the most current data available, and in
collaboration with epidemiologic experts and analysts within
the countries assessed [4]. These ‘‘business as usual’’ forecasts
from 2004 to 2020 are characterized by the absence of
behavioral change or ART scale-up in future years. Combined
with the natural dynamics of the epidemic, these assumptions
result in a relatively stable HIV prevalence rate.
To simulate the effects of prevention and treatment on
HIV/AIDS incidence, prevalence, and mortality, we ﬁrst
adapted the analytic approach used in the previously
described Goals model [3] to allow explicit modeling of
treatment effects, and calibrated the model to the baseline
projections for three African regions (East, West/Central, and
Southern) (see Protocol S1 for more details). In line with the
predominant epidemiologic pattern in sub-Saharan Africa of
HIV spreading through heterosexual contact, the model
divides the sexually active population into ﬁve different
interacting risk groups: single men, single women, married
men, married women, and female sex workers. In sub-
Saharan Africa HIV is transmitted via other modes at
comparatively low levels, and these modes were therefore
not considered in our analyses.
The model includes underlying regional demography,
acquisition of HIV and other sexually transmitted infections
(STIs), progression from HIV to AIDS, and progression from
AIDS to death. Annual risks of HIV infection in each risk
group depend on the number of partnerships, the number of
sex acts per partnership, HIV prevalence among partners and
condom use. These risks are magniﬁed by the presence of
other STIs [14] and also vary as a function of the time since
infection, with the highest risks during acute infection,
followed by lower levels that persist until viral loads rise
with the onset of clinical AIDS [15,16,17].
The regional models were calibrated as follows: ﬁrst,
plausible ranges were speciﬁed for model parameters
governing sexual behavior and biological factors (e.g., trans-
mission risks and cofactor effects of other STIs) based on
review of published studies and survey results; second,
multiple simulations were undertaken by sampling values
from each of the ranges and recalculating the model for each
set of sampled parameter values; third, model ﬁt was assessed
by comparing modeled prevalence for adult males and
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fourth, the best-ﬁtting parameter set in each regional model
was selected for the purpose of scenario analysis (see Protocol
S1).
Alternative Scenarios for Prevention and Treatment
Potential impacts of prevention efforts at a given coverage
level were based on previously published estimates [3] for a
comprehensive package of 12 interventions that included
mass media campaigns, voluntary counseling and testing,
peer counseling for sex workers, school-, youth- and work-
place-based programs, condom promotion and distribution,
treatment for STIs, and prevention of mother-to-child
transmission. The comprehensive package described by
Stover and colleagues also included interventions such as
harm reduction for injecting drug users and peer outreach
for men who have sex with men, which we have not modeled
for sub-Saharan Africa. Impacts were captured in terms of
changes in condom use, sexual partnerships, treatment-
seeking for STIs, and age at ﬁrst sex. The impacts of
treatment included increased survival by a median of 3 y,
reductions in transmission probabilities given contact with an
infected partner, and behavior change.
We examined a range of alternative scenarios based on
various levels and effectiveness of prevention interventions,
with and without successful attainment of the 3 by 5
treatment target for sub-Saharan Africa:
Baseline (‘‘business as usual’’). Risk behaviors are main-
tained at current levels, and no treatment scale-up occurs.
This is simply the baseline scenario that produces a relatively
stable prevalence rate over the duration of the projection,
with the number of people living with HIV and the number of
new infections rising slowly over time because of population
growth.
Treatment-centered response. In two alternative scenarios,
the 3 by 5 target of 50% coverage of those in need of
treatment by the end of 2005 is attained, and scale-up
continues to reach 80% ART coverage of those in need by
2010, maintained at 80% thereafter. In an ‘‘optimal ART
effects’’ scenario, we assumed that treatment reduces trans-
missibility by 99%, and that those under treatment have 50%
lower annual partnership numbers and two times higher
condom use than other adults. With a response that focuses
primarily on treatment, it is assumed that behavior in the
general community of infected and uninfected adults is
unchanged from the baseline. In an alternative ‘‘mixed ART
effects’’ scenario, less optimistic assumptions were made: that
treatment reduces transmissibility only to the same levels as
in asymptomatic infected individuals (two-thirds reduction
from no treatment), and that behavior in treated patients is
the same as in other adults. To capture the possibility of
behavioral disinhibition in response to treatment availability,
we assumed that condom use declines by 10% in both treated
patients and the general community, with other behaviors
unchanged. The potential for disinhibition is suggested
primarily by experience in some developed countries, where
condom use increased dramatically in the populations at
highest risk prior to the introduction of ART but then
declined; the likelihood and magnitude of reductions in
condom use in sub-Saharan Africa, where such prevention-
induced changes generally are much less prominent today,
might be questioned. We therefore considered in sensitivity
analyses a variant of this scenario that excludes disinhibition
but preserves all other assumptions.
Prevention-centered response. In the absence of wide
availability of treatment, reﬂecting weaker political and social
support for HIV control efforts, we modeled a scenario in
which the comprehensive prevention package described
previously [3] has only partial effectiveness at the population
level, and no ART scale-up occurs. As evidence about the
magnitude of treatment–prevention interactions remains
limited, we considered a reduction of 50% from the full
impact as a base case and examined a range of reductions
from 25% to 75% in sensitivity analyses.
Combined response. We examined two scenarios combin-
ing treatment and prevention efforts, reﬂecting either
optimistic or pessimistic possibilities. In the optimistic
scenario, treatment strengthens prevention efforts. ART
coverage is the same as in the two treatment-centered
scenarios, with optimal assumptions about treatment impact
on transmissibility and patient behavior. It is assumed that
widespread availability of treatment enables the full impact
of prevention efforts to be attained as described by Stover et
al. [3]. In a more pessimistic scenario, an emphasis on
treatment leads to less effective implementation of preven-
tion. This scenario includes the mixed assumptions about
ART effects (excluding disinhibition in the general commun-
ity), and assumes only 25% attainment of the maximum
potential impact of prevention efforts.
Additional scenarios could include pessimistic assumptions
about limited ART scale-up levels and timing, emergence of
large-scale drug resistance resulting from low adherence, or
other possible unintended outcomes of wider treatment.
Certainly, large-scale treatment efforts will demand close
monitoring of adverse effects. However, experience with
treatment programs in developing countries has been
encouraging thus far, with reported adherence levels that
are at least as high as those in developed countries [18,19].
Results
In the baseline projections for sub-Saharan Africa, the
annual number of new adult HIV infections rises from 2.4 to
3.7 million between 2004 and 2020, and adult AIDS mortality
rises from 1.8 to 2.6 million (Figure 1). If scale-up of ART
reaches the 3 by 5 target and eventually expands to 80%
coverage, without any behavior change in the broader
community (treatment-centered response/optimal ART ef-
fects), the annual number of new infections could be reduced
by up to 6% compared to baseline by 2020. Mortality would
initially decline by 33% but long-term trends would converge
toward the baseline. We note that total annual death numbers
indicate broad trends in mortality but mask more subtle
health gains in the form of years added to individuals’ lives.
With less optimistic assumptions (treatment-centered
response/mixed ART effects), the number of new infections
rises, to 4.3 million per year by 2020 (a 14% increase);
mortality trends are similar to the optimistic scenario in the
short term, but worse in the long term, even compared to the
baseline. Excluding the assumption of reduced condom use
through disinhibition from the treatment-centered/mixed
effects scenario has minimal effect on the results, lowering
the number of new infections in 2020 by only 2% compared
to the scenario that includes disinhibition.
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on the number of new infections, lowering annual incidence
by more than half by 2020. The long-term mortality trend is
more favorable in the prevention-centered scenario than in
the treatment-centered scenario because of reduced inci-
dence, but prevention would produce negligible mortality
beneﬁts in the near- and mid-term future in comparison to
strategies that include ART. Alternative assumptions regard-
ing overall effectiveness in a prevention-centered response
produce results that scale as expected, with reductions in
annual incidence of 34% to 64% and reductions in annual
mortality of 20% to 42% by 2020.
If treatment and effective prevention are scaled up jointly
in a combined response, the beneﬁts in terms of both
infections and deaths averted could be substantially higher. In
an optimistic scenario in which treatment programs support
expanded prevention, the annual number of new infections
would be 74% lower and annual mortality would be 47%
lower by 2020, compared to baseline. It is worth noting that
the long-term decline in AIDS deaths is driven more by
prevention of new infections than by direct survivorship
beneﬁts from ART. In a pessimistic scenario in which a more
narrow treatment focus limits effective prevention, the
overall beneﬁts are much more modest, with 26% and 16%
reductions, respectively, in new infections and mortality by
2020 compared to the baseline.
Prevalence rises by 7% in the optimal and by 27% in the
mixed treatment-centered scenarios by 2020, as longer
survival for treated patients offsets reductions in new
infections through reduced transmissibility (and risk reduc-
tions among treated patients in the more optimistic scenario)
(Figure S1). In scenarios that include prevention efforts,
prevalence declines by 41% in the prevention-centered
scenario, by 53% in the optimistic combined response, and
by 6% in the pessimistic combined response by 2020.
The total number of infections averted through a com-
bined response would be 29 million over the period 2004 to
2020 if treatment enhances prevention, a beneﬁt that is ten
times greater than that of a strategy which focuses on
treatment only, even with optimal assumptions, and 51%
greater than that of a strategy which focuses on (less effective)
prevention alone (Table 1). If a treatment focus limits the
effectiveness of prevention, on the other hand, the total
number of averted infections between 2004 and 2020 would
be 9 million. Similarly, the beneﬁts of a combined response in
terms of mortality reductions are considerably higher under
optimistic circumstances than the beneﬁts of either treat-
ment only or prevention only, with 10.1 million deaths
averted (27%) through 2020 when treatment enhances
prevention, compared to 5.0 million (13%) in the optimal-
effects treatment only scenario, 3.5 million (9%) in the
mixed-effects treatment only scenario, and 4.8 million (13%)
with prevention only. Under more pessimistic assumptions
about treatment–prevention interactions, the combined
response would avert 5.8 million deaths (16%). Table 1 also
reports total beneﬁts of the various strategies over the shorter
term, in which the ranking of alternatives is similar with
regard to the total number of infections averted, but
mortality reductions are attributable almost exclusively to
treatment.
Combining treatment with prevention efforts will reduce
the resource needs for treatment substantially in the long
term (Figure 2). In the various scenarios the numbers of
people being treated in 2020 ranges from 9.2 million in the
treatment only (mixed effects) scenario, to 4.2 million in the
optimistic combined response scenario.
Discussion
In this paper, we have examined the potential epidemio-
Figure 1. HIV Incidence and AIDS Mortality among Adults in Sub-Saharan Africa, 2003–2020, under Different Intervention Scenarios
(A) HIV incidence.
(B) AIDS mortality.
DOI: 10.1371/journal.pmed.0020016.g001
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of alternative scenarios reﬂecting varying implementation of
strategies for prevention and treatment. Although we focus in
particular on population health outcomes and epidemiologic
trends, we recognize that there are numerous other social,
economic, and individual health effects of interventions
including ART that are beyond the scope of this analysis.
We also restrict our focus in this paper to sub-Saharan Africa,
where the overwhelming majority of people living with and
dying from HIV/AIDS reside; however, our ﬁndings have
broader applicability and more general implications in the
worldwide ﬁght against HIV/AIDS, which we highlight here.
The Potential for Treatment to Enhance Prevention Must
Be Exploited
Effective prevention requires more than having sufﬁcient
funds to offer information and services. It also requires an
environment that encourages people to internalize messages
about risky behavior and to adopt actual behavior change,
and allows people to utilize services such as testing and
counseling without fear of stigma or discrimination. Stone-
burner and Low-Beer have argued that the supportive social
and political environment in Uganda allowed people to
discuss AIDS with family members and close friends, which
led to greater behavior change than in Kenya or Zambia
where most people received information from mass media
only [20]. People have little reason to seek HIV testing when a
positive result brings only negative consequences, whereas
widespread availability of treatment provides a major
incentive for people to learn their serostatus.
Involving communities and family members in the delivery
of treatment—for example, as treatment monitors—offers
unique entry points for effective prevention activities and a
lever for population-wide behavior change. Experience with
community roll-out of treatment programs has shown, for
example, that uptake of voluntary counseling and testing
increased by 300% in one year of roll-out in Haiti, and by a
factor of 12 in Khayelitsha, South Africa, after treatment
introduction [21,22]. A study targeting nine commuter sites in
South Africa found the highest levels of condom use,
willingness to use a female condom, and willingness to have
an HIV test in Khayelitsha, a difference that may be
attributed largely to the availability of ART and comprehen-
sive AIDS care [23]. If increased uptake of voluntary
counseling and testing is indicative of broader prevention
effectiveness where ART is available, we estimate that over
50% more new infections and more than twice as many
deaths could be avoided through a combined response
compared to prevention alone. In contrast, if a narrow
treatment scale-up leads to reduced effectiveness of preven-
tion, short-term mortality reductions will come at the
expense of longer-term progress in stemming the tide of
the epidemic.
During most of the past 15 years, efforts to address the
AIDS epidemic in sub-Saharan Africa have focused on
Table 1. Total New Adult Infections and Deaths in Sub-Saharan Africa, 2004–2010 and 2004–2020, under Different Intervention
Scenarios
Timeframe Scenario Total New
Adult Infections,
Millions
Infections
Averted Compared
to Baseline,
Millions (Percent)
Total Adult
Deaths, Millions
Deaths Averted
Compared to Baseline,
Millions (Percent)
Through 2010 Baseline 18.9 — 14.0 —
Treatment-centered (optimal effects) 18.1 0.9 (5%) 11.0 3.1 (22%)
Treatment-centered (mixed effects) 19.8 0.8 (4%) 11.0 3.0 (22%)
Prevention-centered 14.9 4.0 (21%) 13.9 0.2 (1%)
Combined response (optimistic) 12.1 6.8 (36%) 10.8 3.2 (23%)
Combined response (pessimistic) 17.2 1.8 (9%) 11.0 3.1 (22%)
Through 2020 Baseline 52.3 — 37.4 —
Treatment-centered (optimal effects) 49.2 3.0 (6%) 32.4 5.0 (13%)
Treatment-centered (mixed effects) 57.4 5.1 (10%) 33.9 3.5 (9%)
Prevention-centered 33.2 19.1 (36%) 32.6 4.8 (13%)
Combined response (optimistic) 23.4 28.8 (55%) 27.3 10.1 (27%)
Combined response (pessimistic) 43.6 8.7 (17%) 31.6 5.8 (16%)
DOI: 10.1371/journal.pmed.0020016.t001
Figure 2. Number of Persons on ART in Sub-Saharan Africa, 2004–2020,
under Various Scenarios
DOI: 10.1371/journal.pmed.0020016.g002
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overall these efforts have not achieved their goals. The advent
of vastly expanding treatment programs in the coming years,
if opportunities to capitalize on broadened political support
and community mobilization can be seized, offers the
potential to enhance prevention effectiveness and avert
many new infections and deaths.
Only Effective Prevention Will Make Treatment Affordable
in the Long Run
While prevention programs are unlikely to achieve full
impact in the absence of treatment, so too is the impact of
treatment programs reduced if vigorous prevention efforts
are absent. Without effective prevention, the number of
people requiring care and treatment will grow each year. As
more and more people are kept alive with ART the treatment
burden will become enormous unless effective prevention
reduces the number of people becoming newly infected.
Without effective prevention programs, we project that the
number of people receiving treatment will grow to 6.3 million
by 2010 and up to 9.2 million by 2020 in Africa alone to
achieve 80% coverage of those in urgent need. Meeting this
need would require a tremendous increase in ﬁnancing,
human capacity and infrastructure that might not be
attainable.
If effective prevention programs are combined with treat-
ment programs, the same level of 80% ART coverage would
be achieved by treating 5.8 million in 2010 and 4.2 million in
2020. In other words, the same goal could be attained at a far
lower treatment cost and with a much greater chance of
sustainability.
A Successful Global Response Cannot Rely on Either
Prevention or Treatment Alone
Over the long term, it is effective prevention that will
reduce the burden of illness due to AIDS and the number of
people in need of ART. The lessons learned in the
industrialized world have to be taken on board. The
availability of treatment and the shift in focus away from
very effective prevention programs has led to increases in
unsafe sexual behavior, STIs, and HIV transmission in some
settings [9,10,11]. There is no doubt that effective therapy can
extend and improve the quality of life for those who are
treated, but it also must be integrated into a comprehensive
community response to HIV so that it can enhance the
effectiveness of prevention efforts. Long-term, sustained
progress in the ﬁght against AIDS demands more than an
exclusive focus on either prevention or treatment alone.
Prevention makes treatment affordable, and treatment can
make prevention more effective.
Countries in sub-Saharan Africa are faced with the most
devastating epidemic of our times. We now have the unique
opportunity to derive the maximum impact from available
resources. The results from our analyses show how potential
synergies between prevention and treatment could be
translated into considerable health beneﬁts at the population
level. But synergies do not mean simply that prevention and
treatment are pursued in parallel. When whole communities
become involved in the scale-up of treatment access—as will
be necessary to achieve the ambitious treatment targets
deﬁned by the 3 by 5 campaign—crucial opportunities can be
created for increasing their involvement in prevention
activities. Only if interactions with patients, family, and
community members occasioned by the provision of treat-
ment are also used to reinforce prevention, and only if
prevention workers have an opportunity to refer those in
need to care and treatment, will we move at last from slogans
to impact.
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2003–2020, under Different Intervention Scenarios
Found at DOI: 10.1371/journal.pmed.0020016.sg001 (80 KB EPS).
Protocol S1. Technical Appendix
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Patient Summary
Background. Infections from HIV continue to increase, especially in sub-
Saharan Africa. The World Health Organization has a plan to get more
than 3 million people on treatment by 2005 (the ‘‘3b y5 ’’ initiative);
however, the overall effect of this plan on the population’s health is
uncertain, and will depend on the balance between treatment and
prevention efforts.
What Did the Researchers Do? They tried to predict the number of new
infections and deaths each year in sub-Saharan Africa from now until
2020 depending on whether control efforts focused on prevention,
treatment, or both. What they found was that by far the most effective
way of decreasing new infections and deaths was to combine the two
approaches, and that by doing so more than 29 million new infections
and 10 million deaths might be prevented compared with continuing at
current levels of prevention and care.
Why Is This Information Important, and Who Will Use It? Despite the
huge amounts of money directed at HIV/AIDS, because the problem is so
vast, the resources are not enough. Hence it is important to target these
resources effectively. Policy makers around the world could use
information like this to decide where best to direct attention and
funding to combat HIV/AIDS.
Where Can I Find More Information?
Joint United Nations Programme on HIV/AIDS, AIDS epidemic update,
December 2004: http://www.unaids.org/wad2004/report.html
World Heath Organization, 3 by 5 Initiative: http://www.who.int/3by5/
Global HIV Prevention Working Group: http://www.kff.org/hivaids/
hivghpwgpackage.cfm
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